TRIUMPH-4 (28.7% weight loss, knee OA population, December 2025), TRIUMPH-1 (28.3%, general obesity, May 2026), TRANSCEND-T2D-1 (-2.0% HbA1c, 16.8% weight loss, June 2026), TRIUMPH-2 (20.8% weight loss, obesity + diabetes, July 23, 2026), and TRIUMPH-3 (22.6% weight loss, obesity + cardiovascular disease, July 23, 2026) have all reported positive results
SURMONT-5 for weight loss: Wegovy vs
Open communication ensures your semaglutide therapy remains safe and effective, and your treatment can be adjusted or supplemented to restore your energy and momentum
AFB 2007)
In clinical trials, patients were sometimes allowed to stay at a lower dose for up to 8 weeks if needed to let side effects settle down
Se toma disuelto en agua